RecruitingPhase 3NCT06596252
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Studying Primary eosinophilic gastrointestinal disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dr. Falk Pharma GmbH
- Principal Investigator
- Alfredo J Lucendo, MD, PhDDepartment of Gastroenterology, Hospital General de Tomelloso, Spain
- Intervention
- Budesonide(drug)
- Enrollment
- 308 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2021 – 2027
Study locations (26)
- Dr. Falk Investigational Site, Scottsdale, Arizona, United States
- Dr. Falk Investigational Site, Little Rock, Arkansas, United States
- Dr. Falk Investigational Site, La Jolla, California, United States
- Dr. Falk Investigational Site, Lomita, California, United States
- Dr. Falk Investigational Site, San Diego, California, United States
- Dr. Falk Investigational Site, Doral, Florida, United States
- Dr. Falk Investigational Site, New Port Richey, Florida, United States
- Dr. Falk Investigational Site, Boise, Idaho, United States
- Dr. Falk Investigational Site, Houma, Louisiana, United States
- Dr. Falk Investigational Site, Marrero, Louisiana, United States
- Dr. Falk Investigational Site, Boston, Massachusetts, United States
- Wyoming, Ann Arbor, Michigan, United States
- Dr. Falk Investigational Site, Wyoming, Michigan, United States
- Dr. Falk Investigational Site, Rochester, Minnesota, United States
- Dr. Falk Investigational Site, Freehold, New Jersey, United States
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06596252 on ClinicalTrials.govOther trials for Primary eosinophilic gastrointestinal disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06851559A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 WeeksPhathom Pharmaceuticals, Inc.
- RECRUITINGNANCT06817213Patient-Centered Decision Support for Eosinophilic EsophagitisUniversity of Michigan
- RECRUITINGNCT06695897A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in GermanySanofi
- ACTIVE NOT RECRUITINGPHASE4NCT06352073Dupilumab for Eosinophilic Esophagitis With Severe StricturesUniversity of North Carolina, Chapel Hill
- RECRUITINGNANCT06381219Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot TrialUniversitaire Ziekenhuizen KU Leuven
- RECRUITINGNCT06991881Eosinophilic Esophagitis: Towards Improved ManagementOslo University Hospital
- RECRUITINGNANCT06501274Capsule Sponge Study in Eosinophilic OesophagitisEast and North Hertfordshire NHS Trust
- RECRUITINGNANCT05730933An Intervention Study to Improve Therapeutic Compliance in Adult Patients With Eosinophilic Esophagitis.Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See all trials for Primary eosinophilic gastrointestinal disease →